Monopar Therapeutics Inc. (NASDAQ:MNPR) CEO Sells $672,000.00 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) CEO Chandler Robinson sold 16,800 shares of the business's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the chief executive officer directly owned 73,472 shares of the company's stock, valued at $2,938,880. This represents a 18.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Monopar Therapeutics Stock Down 1.6%

Monopar Therapeutics stock traded down $0.77 during mid-day trading on Friday, hitting $46.48. 30,457 shares of the company's stock were exchanged, compared to its average volume of 363,996. The firm has a market capitalization of $284.46 million, a P/E ratio of -13.36 and a beta of 1.01. Monopar Therapeutics Inc. has a fifty-two week low of $1.72 and a fifty-two week high of $54.30. The company's 50 day simple moving average is $35.86 and its 200-day simple moving average is $36.31.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.27. Research analysts expect that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds have recently bought and sold shares of MNPR. AlphaQuest LLC acquired a new position in Monopar Therapeutics during the first quarter valued at approximately $44,000. JPMorgan Chase & Co. acquired a new position in shares of Monopar Therapeutics during the fourth quarter valued at about $45,000. Gerber LLC acquired a new stake in shares of Monopar Therapeutics in the 1st quarter worth about $204,000. OMERS ADMINISTRATION Corp bought a new stake in Monopar Therapeutics in the 1st quarter worth about $328,000. Finally, Jane Street Group LLC bought a new stake in Monopar Therapeutics in the 1st quarter worth about $377,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on MNPR. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday, April 1st. Chardan Capital began coverage on Monopar Therapeutics in a research note on Monday, June 23rd. They set a "buy" rating and a $60.00 price target on the stock. Cantor Fitzgerald began coverage on Monopar Therapeutics in a research note on Monday, July 7th. They set an "overweight" rating and a $74.00 price target on the stock. Wall Street Zen upgraded Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Jones Trading restated a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $60.00.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.